MS gray matter loss reveals network-based mechanisms
-
By
-
Andrea Surnit
-
November 16, 2026
-
5 min
By
Andrea Surnit
November 16, 2026
The phase 3 OVERLORD-MS trial compared 2 anti-CD20 therapies in previously untreated adults with newly diagnosed relapsing multiple sclerosis and recent inflammatory disease activity.
July 7, 2026
The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.
June 15, 2026